Brokers Set Expectations for Kura Oncology FY2025 Earnings

Kura Oncology, Inc. (NASDAQ:KURA) – Cantor Fitzgerald issued their FY2025 earnings estimates for Kura Oncology in a report issued on Tuesday, March 4th. Cantor Fitzgerald analyst L. Watsek forecasts that the company will earn ($2.94) per share for the year. Cantor Fitzgerald currently has a “Strong-Buy” rating on the stock. The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share.

Several other research analysts also recently issued reports on KURA. TD Cowen reaffirmed a “buy” rating on shares of Kura Oncology in a research note on Thursday, November 21st. Bank of America lowered their price target on shares of Kura Oncology from $36.00 to $29.00 and set a “buy” rating for the company in a report on Friday, November 22nd. JMP Securities restated a “market outperform” rating and issued a $28.00 target price on shares of Kura Oncology in a research note on Thursday, February 6th. Scotiabank decreased their target price on Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating for the company in a research note on Wednesday, January 8th. Finally, BTIG Research cut Kura Oncology from a “buy” rating to a “neutral” rating in a research report on Thursday, February 6th. Four investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Kura Oncology currently has an average rating of “Moderate Buy” and an average target price of $27.13.

Kura Oncology Stock Up 0.5 %

Kura Oncology stock opened at $7.37 on Thursday. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. The stock’s 50 day moving average price is $8.07 and its 200 day moving average price is $13.56. Kura Oncology has a 1-year low of $6.98 and a 1-year high of $24.17. The company has a market cap of $573.12 million, a PE ratio of -3.12 and a beta of 0.85.

Kura Oncology (NASDAQ:KURA) last posted its earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.43. The firm had revenue of $53.88 million during the quarter, compared to analysts’ expectations of $57.96 million.

Insider Buying and Selling at Kura Oncology

In other Kura Oncology news, SVP Thomas James Doyle sold 4,949 shares of Kura Oncology stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.63. Following the transaction, the senior vice president now owns 88,193 shares of the company’s stock, valued at approximately $694,078.91. The trade was a 5.31 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Mollie Leoni sold 4,963 shares of the company’s stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the transaction, the insider now directly owns 88,253 shares of the company’s stock, valued at approximately $694,551.11. The trade was a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 11,729 shares of company stock worth $92,307. Company insiders own 5.50% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Virtus ETF Advisers LLC increased its stake in shares of Kura Oncology by 71.6% during the fourth quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company’s stock worth $64,000 after purchasing an additional 3,061 shares during the period. Point72 DIFC Ltd bought a new stake in shares of Kura Oncology in the third quarter valued at about $146,000. Harbor Advisors LLC bought a new position in Kura Oncology during the fourth quarter worth about $87,000. E Fund Management Co. Ltd. acquired a new stake in Kura Oncology in the 4th quarter worth about $90,000. Finally, Erste Asset Management GmbH acquired a new stake in Kura Oncology in the 3rd quarter worth about $215,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.